We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Andrx Relinquishes 180-Day Exclusivity For Wellbutrin Generic, Ceding Ground To Eon

Law360 (March 23, 2004, 12:00 AM EST) -- Generic drug maker Andrx Corp. has relinquished its right to a 180-day period of marketing exclusivity for the 150mg strength of Wellbutrin SR(R), a best-selling antidepressant from GlaxoSmithKline.

Andrx had filed suit against rival generic maker Eon in Florida, arguing that it was the first-to-file an Abbreviated New Drug Application (ANDA) for Wellbutrin, and therefore entitled to the 180-day market exclusivity period provided by law.

Andrx claimed in the lawsuit that the FDA improperly granted approval of Eon's generic tablets.

Under Hatch-Waxman rules, the first company...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.